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In pulmonary arterial smooth muscle, Ca2 release from the
sarcoplasmic reticulum (SR) via ryanodine receptors (RyRs)may
induce constriction and dilation in a manner that is not mutu-
ally exclusive. We show here that the targeting of different sar-
coplasmic/endoplasmic reticulum Ca2-ATPases (SERCA) and
RyR subtypes to discrete SR regions explains this paradox.
Western blots identified protein bands for SERCA2a and
SERCA2b, whereas immunofluorescence labeling of isolated
pulmonary arterial smoothmuscle cells revealed striking differ-
ences in the spatial distribution of SERCA2a and SERCA2b and
RyR1, RyR2, and RyR3, respectively. Almost all SERCA2a and
RyR3 labeling was restricted to a region within 1.5 m of the
nucleus. In marked contrast, SERCA2b labeling was primarily
found within 1.5 m of the plasma membrane, where labeling
for RyR1 was maximal. The majority of labeling for RyR2 lay in
between these two regions of the cell. Application of the vaso-
constrictor endothelin-1 induced global Ca2 waves in pulmo-
nary arterial smooth muscle cells, which were markedly attenu-
ated upon depletion of SR Ca2 stores by preincubation of cells
with the SERCA inhibitor thapsigargin but remained unaffected
after preincubation of cells with a second SERCA antagonist,
cyclopiazonic acid. We conclude that functionally segregated
SR Ca2 stores exist within pulmonary arterial smooth muscle
cells. One sits proximal to the plasmamembrane, receives Ca2
via SERCA2b, and likely releasesCa2 via RyR1 tomediate vaso-
dilation. The other is located centrally, receives Ca2 via
SERCA2a, and likely releasesCa2 via RyR3 andRyR2 to initiate
vasoconstriction.
Previous studies on smooth muscle have provided evidence
in support of the view that the sarcoplasmic reticulum (SR)2
may be functionally segregated (1, 2). Evidence suggests that
such segregation may confer functionally segregated Ca2
stores that may be mobilized differentially and in a stimulus-
specific manner. Briefly, it has been shown that: 1) preincuba-
tion of pulmonary arterial smoothmuscle with ryanodine, both
with and without caffeine, may block Ca2 signals via ryano-
dine receptor (RyR) activation without affecting Ca2signals
generated in response to IP3 (3, 4); 2) both caffeine-sensitive
and caffeine-insensitive SR stores exist in cultured mesenteric
arterial smooth muscle and airway smooth muscle cells, with
only the latter sensitive to depletion by the sarco/endoplasmic
reticulum Ca2-ATPase (SERCA) antagonist cyclopiazonic
acid (5–7); and 3) activation of -adrenoceptors on airway
smooth muscle cells may increase the Ca2 concentration in
the subplasmalemmal region while decreasing the Ca2 con-
centration in the central cytoplasmic region (8).
Our investigations on pulmonary arterial smooth muscle
have provided further support for the view that functionally
segregated SR stores may exist. We demonstrated that -adre-
noreceptor activation mobilizes Ca2, via RyRs, from a cyclo-
piazonic acid-sensitive SR store proximal to the plasma mem-
brane and thereby recruits large conductance Ca2-activated
K (BKCa) channels, leading to smoothmuscle cell hyperpolar-
ization and pulmonary artery dilation (9). In itself this may not
seem surprising, except for the fact that in these studies cyclo-
piazonic acid was without effect on artery constriction by pros-
taglandin F2, which induces constriction in part by mobilizing
ryanodine-sensitive SR stores (10, 11). Therefore, both precon-
striction and subsequent vasodilation in response to -adreno-
receptor activation were, at least in part, mediated by Ca2
release from what is considered to be a continuous (i.e. the
same) SR store (12). This paradox and the findings of others (see
above) could be explained by the presence of two functionally
and spatially segregated SR compartments, each equipped with
a specific SERCA-type Ca2 pump and a specific RyR-type
Ca2 release channel (for review see Ref. 13). This is quite pos-
sible given that all three RyR subtypes (14) are expressed in
arterial smooth muscle (15–18), and a family of three genes
encodes multiple SERCA pumps (19–22), namely the alterna-
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tively spliced isoforms SERCA1a and SERCA1b (23, 24), the
SERCA2a and SERCA2b isoforms (23, 25–28), and SERCA3a–f
(22, 29, 30). We therefore sought to determine whether or not
multiple SERCA isoformswere expressed in pulmonary arterial
smooth muscle cells and, if so, whether or not different SERCA
and RyR subtypes were differentially distributed in pulmonary
arterial smooth muscle cells in a manner consistent with the
presence of two functionally segregated SR compartments.
EXPERIMENTAL PROCEDURES
All of the experiments were performed under the United
Kingdom Animals (Scientific Procedures) Act of 1986. Adult
male Wistar rats (150–300 g) were sacrificed by cervical dislo-
cation. Skeletal muscle, brain, heart, and lungs were removed
and placed on ice in physiological salt solution of the following
composition: 130 mmol/liter NaCl, 5.2 mmol/liter KCl, 1
mmol/liter MgCl2, 1.7 mmol/liter CaCl2, 10 mmol/liter glu-
cose, and 10 mmol/liter Hepes, pH 7.45.
RT-PCR—Total RNAwas extracted from second and third order
branchesofthepulmonaryarterialtree,heart,brain,andskeletalmus-
cle using TRIzol reagent according to the manufacturer’s instruc-
tions (Invitrogen).Reverse transcriptionwascarriedoutusing6gof
RNA and 200 units of Moloney murine leukemia virus (Promega),
and PCRwas performed on 1l of cDNAwith 1 unit/l TaqDNA
polymerase (Biogene) as previously described (31). Theprimers used
for each receptor are shown in Table 1. All of the primer sequences
were checked against the GenBankTM, and no cross-reactivity was
found. The RT-PCR products over 40 cycles of amplification were
resolved by electrophoresis in 1% agarose gels and visualized under
UV illumination using an image capture system (Genesnap image
analysis system; Syngene).
Western Blotting—Second order branches of the pulmonary
arterial tree, heart, brain, and skeletal muscle were rapidly fro-
zen in liquid nitrogen. Small segments of tissue were ground to
a powder under liquid nitrogen and homogenized in an appro-
priate volume of ice-cold buffer (50mmol/liter Tris, 150mmol/
liter NaCl, 50 mmol/liter NaF, 5 mmol/liter sodium pyrophos-
phate, 1 mmol/liter EDTA, 1 mmol/liter EGTA, 1 mmol/liter
dithiothreitol, 0.1 mmol/liter benzamidine, 0.1 mmol/liter
phenylmethylsulfonyl fluoride, 0.2 mmol/liter mannitol, 0.1%
(v/v) Triton, pH 7.4) using amotor-driven pestle. The homoge-
natewas kept on ice for 30min and then centrifuged (7500 rpm,
5min, 4 °C). The supernatants were removed, and their protein
concentrations were determined.
Equal amounts of homogenates (free of nuclear and whole cell
debris) were separated on 10% bisacrylamide gels (NuPAGETM
electrophoresis system; Invitrogen) and blotted onto nitrocellu-
lose membranes. The blots were probed with sequence-specific
antibodies for SERCA1 (1:2500,mousemonoclonal, raised against
residues 199–505 of rabbit SERCA1; Abcam), SERCA2a
(1:10000, rabbit polyclonal, raised against residues 989–997 of
pig SERCA2a; F.Wuytack, Leuven, Belgium (30, 32)), SERCA2b
(1:5000, rabbit polyclonal, raised against residues 1032–1043 of
pig SERCA2b; F. Wuytack, Leuven, Belgium (30, 32)), and
SERCA3 (1:500, rabbit polyclonal, raised against residues
29–39 of mouse SERCA3; Abcam). Every blot was also probed
with a polyclonal antibody for actin to ensure equal protein
loading (Sigma) alongside the SERCA antibodies. Detection
was performed with horseradish peroxide-conjugated second-
ary antibodies using the ECL system (GE Healthcare).
SmoothMuscle Cell Isolation—Single arterial smoothmuscle
cells were isolated from second order branches of the pulmo-
nary artery. Briefly, the arterieswere dissected out and placed in
low Ca2 solution of the following composition: 124 mMNaCl,
5 mM KCl, 1 mM MgCl2, 0.5 mM NaH2PO4, 0.5 mM KH2PO, 15
mMNaHCO3, 0.16mMCaCl2, 0.5mMEDTA, 10mMglucose, 10
mM taurine, and 10mMHepes, pH 7.4. After 10min the arteries
were placed in the same solution containing 0.5 mg/ml papain
and 1 mg/ml bovine serum albumin and kept at 4 °C overnight.
The following day 0.2 mmol/liter 1,4-dithio-DL-threitol was
added to the solution to activate the protease, and the prepara-
tion was incubated for 1 h at room temperature (22 °C). The
tissue was then washed three times in fresh low Ca2 solution
without enzymes, and single smooth muscle cells were isolated
by gentle trituration with a fire-polished Pasteur pipette. The
cells were stored in suspension at 4 °C until required.
Immunocytochemistry—The cells were placed onto poly-D-
lysine-coated coverslips, fixed using ice-cold methanol for 15
min, permeabilized by three 5-min washes with 0.6% Triton
X-100 in phosphate-buffered saline (pH 7.4) followed by three
5-min washes with blocking solution (1% bovine serum albu-
min, 4% goat serum, and 0.3% Triton X-100 in phosphate-buff-
ered saline, pH 7.4). The cells were incubated overnight at 4 °C
with the sequence-specific antibodies for SERCA2a (1:500) and
SERCA2b (1:500). In addition, paired samples of cells were
incubated overnight at 4 °C with affinity-purified rabbit anti-
RyR1 (1:500; raised against the peptide residues 4476–4486
(33)), anti-RyR2 (1:500; raised against the peptide residues
1344–1365 (34)), and anti-RyR3 (1:500; raised against the pep-
tide residues 4236–4336 (35)). The coverslips were washed
four times with blocking solution and incubated with goat anti-
TABLE 1
Primers for RT-PCR experiments GenBankTM accession numbers NM_058213 (SERCA1), J04023 (SERCA2a), J04022 (SERCA2b), and J05086
(SERCA3)
Gene Primer Sequence Nucleotide positions Predicted product size
bp
SERCA1 Sense CTC ACT TCC AGT CAT CGG GCT AG 3084–3106 340
Antisense GTC AGC TAG TTG CCT TGT CCC TG 3423–3401
SERCA2a Sense CCT GTC CAG TTA CTC TGG GTC 2569–2589 694
Antisense GCT AAC AAC GCA CAT GCA CGC 3262–3242
SERCA2b Sense GCC AAC ATT GCC TAT TCA GTG GCA C 4382–4406 501
Antisense GGA TGT TGG AAG GCA TTG GAG G 4882–4861
SERCA3 Sense CTC WGA GAA CCA GTC ACT GCT GCa 2879–2901 264
Antisense GCT CYC AGG ATT TAC TTC AGG TCCb 3142–3119
a W indicates A or T.
b Y indicates C or T.
SERCA and RyR in SmoothMuscle
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rabbit Texas Red-conjugated secondary antibody (1:200; exci-
tation, 596 nm; emission, 620 nm). Then the coverslips were
washed five times with phosphate-buffered saline and attached
to slides by anti-fade mountant (2.4 g of Mowiol 4–88, 6 g of
glycerol, 2 ml of 0.2 M Tris-HCl, pH 8.5, 2.5% 1,4-
diazabicyclo(2.2.2.)octane) with 4,6-diamino-2-phenylindole
(DAPI, 1 g/ml; excitation, 358 nm; emission, 461 nm). For
controls, the primary antibody was omitted. The images
were acquired using a Deltavision imaging system (Applied
Precision) consisting of an Olympus IX70 inverted micro-
scope with an Olympus PlanApo 60, 1.40 n.a. oil immer-
sion objective and a Photometric CH300 charge-coupled
device camera. Z section (0.2 m) stacks were taken through
cells. The images were deconvolved using Softworx acquisi-
tion and analysis software (Applied Precision) as described
previously (18).
Analysis of Fluorescent Labeling—Three-dimensionally ren-
dered images of pulmonary arterial smooth muscle cells were
obtained using Volocity software (PerkinElmer Life Sciences)
and subdivided into three defined volumes that excluded the
DAPI-labeled nucleus, namely the perinuclear (the area of
the cell located within 1.5 m of the DAPI-labeled nucleus), the
subplasmalemmal (the area of the cell located within 1.5mof
the plasma membrane), and the extraperinuclear regions
(the remaining volume of the cell). The volumes occupied by
these three defined regions were measured, and then the
density of fluorescent labeling in that region was determined
by dividing the volume of protein labeling (e.g. for SERCA2a)
within a given region by the volume of that region as
described in detail previously (18). Thus, data are presented
as the means  S.E. of the volume of labeling per m3 of a
given region (m3/m3).
Ca2 Imaging—Pulmonary arterial smooth muscle cells
(PASMCs) were incubated for 30 min with 5 M Fura-2-AM in
Ca2-free physiological salt solution in an experimental cham-
ber on a Leica DMIRBE inverted microscope and then super-
fused with Fura-2-free physiological salt solution for at least 30
min prior to experimentation. Cytoplasmic Ca2 concentra-
tion was reported by Fura-2 fluorescence ratio (F340/F380 exci-
tation; emission, 510 nm). Emitted fluorescence was recorded
at 22 °C with a sampling frequency
of 0.5 Hz using a Hamamatsu 4880
CCD camera via a Zeiss Fluar 40,
1.3 n.a. oil immersion lens, and
Leica DMIRBE microscope. Back-
ground subtraction was performed
on-line. Analysis was via Openlab
imaging software (Improvision).
Data Presentation and Statistical
Analysis—The data are presented as
the means  S.E. Comparisons
between the groups were carried
out in MINITAB 14 using analysis
of variance followed by a Tukey
post-hoc test. Probability values less
than 0.05 were considered to be sta-
tistically significant.
Drugs and Chemicals—All of the
compounds were from Sigma-Aldrich except horseradish per-
oxidase-conjugated secondary antibodies (Vector Laborato-
ries) and fluorescently tagged secondary antibodies (Jackson
Immunoresearch).
RESULTS
Identification of SERCA Expressed in Pulmonary Arterial
SmoothMuscle—RT-PCRproducts amplified frommRNA that
was extracted from second and third order branches of the rat
pulmonary arterial tree (without endothelium) identified tran-
scripts for all SERCA subtypes after 40 cycles. These were con-
sistent with the predicted sizes for SERCA1, SERCA2a,
SERCA2b, and SERCA3 andmatched the positive controls gen-
erated frommRNA extracted from rat brain, heart, and skeletal
muscle (Fig. 1A). However, it is clear that the level of expression
of SERCA2a and SERCA2b was higher than that observed with
respect to the other subtypes.
The protein expression of SERCA isoforms was determined
by Western blot. Specific antibodies against SERCA1,
SERCA2a, SERCA2b, and SERCA3, respectively, detected ap-
propriate bands of protein with a molecular mass of100 kDa
in the lysate of control tissues, namely those for SERCA1,
SERCA2a, and SERCA3 in skeletal muscle, SERCA2a and
SERCA2b in heart, and SERCA2b in brain (Fig. 1B). However, Fig.
1B clearly shows that protein bands for SERCA2a and SERCA2b,
but not for SERCA1 or SERCA3, were detected in paired samples
from pulmonary arterial smoothmuscle lysates.
SERCA2a and SERCA2b Are Differentially Distributed in
Acutely Isolated Pulmonary Arterial Smooth Muscle Cells—
Using sequence-specific antibodies against SERCA2a and
SERCA2b,we confirmed the functional expression of SERCA2a
and SERCA2b by immunocytochemistry and analyzed their
respective spatial distributions by deconvolution microscopy.
Strikingly, visual inspection of deconvolved images revealed
discrete targeting of SERCA2a and SERCA2b to different
regions of pulmonary arterial smooth muscle cells. Fig. 2A
shows labeling for SERCA2a in an exemplar cell, which was
almost entirely restricted to the perinuclear region. The dimen-
sions of the cell are shown by a bright field image (panel a),
adjacent images of a deconvolved Z-section through the cell
FIGURE 1. SERCA2a and SERCA2b, but not SERCA1 or SERCA3, are functionally expressed in rat pulmo-
naryarterial smoothmuscle.A, RT-PCR fragmentsof SERCA1, SERCA2a, SERCA2b, andSERCA3amplified from
totalmRNAextracted fromsecondand third order branches of thepulmonary arterial tree (PA), skeletalmuscle
(SM), heart (H), and brain (B) mRNAs. The predicted sizes of the PCR products were 340 bp for SERCA1, 694 bp
for SERCA2a, 501bp for SERCA2b, and 264bp for SERCA3. B, Western blots for SERCA1, SERCA2a, SERCA2b, and
SERCA3 in lysates of: smooth muscle from second order branches of the pulmonary arterial tree (PA), skeletal
muscle (SM), heart (H), and brain (B). Each blot was also probed with an antibody selective for actin to ensure
equal protein loading (not shown).
SERCA and RyR in SmoothMuscle
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with the distribution of SERCA2a labeling in red relative to the
DAPI-labeled nucleus in blue (panel b), and a three-dimen-
sional reconstruction of a Z-stack of images showing the distri-
bution of SERCA2a labeling (panel c) as in panel b. Fig. 2A
(panel d) shows the three-dimensional reconstruction again,
but this time with the distribution of labeling depicted by color
across three defined volumes of the cell, namely the perinuclear
region (orange; within 1.5 m of, but excluding, the DAPI-la-
beled nucleus), the extraperinuclear region (pink), and the sub-
plasmalemmal region (light blue; within 1.5 m of the plasma
membrane). Analysis of the distribution by density of SERCA2a
labeling confirmed that it was almost entirely restricted to the
perinuclear region of the cell, with the density of labeling in this
region measuring 0.125  0.019 m3/m3 (p  0.05 when
compared with SERCA2b, see below) compared with 0.003 
0.001 m3/m3 in the extraperinuclear region and 0.003 
0.002m3/m3 in the subplasmalemmal region (p 0.01when
compared with the perinuclear region; Fig. 3C). Inmarked con-
trast, SERCA2b appeared to be primarily located in close prox-
imity to the plasmamembrane. This is evident in Fig. 2B, which
shows an exemplar cell as before, with a bright field image of the
cell (panel a), a single deconvolved Z-section taken through the
cell with the distribution of SERCA2b labeling again in red rel-
ative to theDAPI-labeled nucleus in blue (panel b), and a three-
dimensional reconstruction of the associated Z-stack of images
showing the distribution of labeling for SERCA2b (panel c) as in
panel b. The discrete distribution of SERCA2b labeling in the
three-dimensional image is clearer, however, when depicted by
color (panel d) across the perinuclear region (orange; within 1.5
m of, but excluding, the DAPI-labeled nucleus), the extra-
perinuclear region (pink), and the subplasmalemmal region
(light blue; within 1.5 m of the plasma membrane). The sub-
FIGURE2.SERCA2aandSERCA2baredifferentiallydistributedwithin iso-
lated pulmonary arterial smooth muscle cells. A and B, images show the
distribution of labeling for SERCA2a (A) and SERCA2b (B). Panel a, transmitted
light image of PASMC. Scale bar, 10 m. Panel b, deconvolved Z-section taken
through the cellwith labeling for thegivenSERCAsubtype (red) in relation to the
nucleus (blue) andtheplasmamembrane(dotted line).Panelc, three-dimensional
reconstruction of a series of Z-sections (Z step 0.2m)obtained through the cell
fluorescently labeled as in panel b. Panel d, three-dimensional representation
showing the distribution by color of individual volumes of labeling for the given
SERCA subtype in the perinuclear (orange), extraperinuclear (pink), and subplas-
malemmal (light blue) regions.C, bar chart shows the density of labeling (m3of
labeling perm3; mean S.E.) for SERCA2a and SERCA2bwithin the three des-
ignated regions of isolated PASMCs.
FIGURE 3. RyR1, RyR2, and RyR3 are differentially distributed within iso-
lated pulmonary arterial smooth muscle cells. A–C, images show the dis-
tribution of labeling for RyR1 (A), RyR2 (B), and RyR3 (C). Panel a, transmitted
light image of PASMC. Scale bar, 10 m. Panel b, three-dimensional recon-
struction of a series of Z-sections (Z step 0.2 m) obtained through the cell
fluorescently labeled in relation to the nucleus (blue) and the plasma mem-
brane (dotted line). Panel c, three-dimensional representation showing the
distribution by color of individual volumes of labeling for the given RyR sub-
type in the perinuclear (orange), extraperinuclear (pink), and subplasmale-
mmal (light blue) regions. D, bar chart shows the density of labeling (m3 of
labeling perm3;means S.E.) for each of the RyR subtypeswithin the three
designated regions of isolated PASMCs.
SERCA and RyR in SmoothMuscle
APRIL 30, 2010•VOLUME 285•NUMBER 18 JOURNAL OF BIOLOGICAL CHEMISTRY 13545
 by guest on September 12, 2013http://www.jbc.org/Downloaded from 
plasmalemmal targeting of SERCA2b was confirmed by analy-
sis of the density of labeling, which measured 0.106  0.016
m3/m3 (p  0.01 when compared with SERCA2a) in the
subplasmalemmal region compared with 0.010  0.003 m3/
m3 in the extraperinuclear region and 0.033  0.011 m3/
m3 in the perinuclear region (Fig. 2C; p  0.05 when com-
pared with the subplasmalemmal region). These findings
suggest that SERCA2b serves an SR compartment proximal to
the plasma membrane of pulmonary arterial smooth muscle
cells, whereas SERCA2a serves a discrete SR compartment
located centrally within these cells.
RyR1, RyR2, and RyR3 Are Differentially Distributed in
Acutely Isolated Pulmonary Arterial Smooth Muscle Cells—
Previous studies on RT-PCR products amplified from mRNA
derived from rat pulmonary arterial smooth muscle have
identified transcripts for all three RyR subtypes (17). More-
over, protein expression of each subtype has been confirmed
in pulmonary arterial smooth muscle by Western blot and
immunocytochemistry (17, 18) using affinity-purified se-
quence-specific antibodies that have been shown to be highly
selective for RyR1 (33), RyR2 (34), and RyR3 (35) across a range
of tissues in which they are expressed. Of greatest significance
to the present study, however, is our previous finding that RyR3
may be preferentially targeted to regions of the SR that form
junctional complexes with lysosomes to comprise a trigger
zone for Ca2 signaling by nicotinic acid adenine dinucleotide
phosphate (18), with RyR1 and RyR2 preferentially targeted to
regions of the SR that sit outside of the lysosome-SR junctions.
Using the same affinity-purified antibodies, we therefore com-
pared the distribution of each RyR subtype in cells from sam-
ples paired with those labeled for SERCA2a and SERCA2b, to
determine whether or not SERCA2a and SERCA2b, respec-
tively, clustered in regions of the cell occupied by different RyR
subtypes to constitute functionally segregated SR compart-
ments; the antibodies against the SERCA and RyR subtypes
were all raised in rabbits and therefore precluded double label-
ing. The spatial distribution of each RyR subtype was analyzed
as for SERCA (see above) and revealed discrete targeting of
RyR1, RyR2, and RyR3. Fig. 3A shows labeling for RyR1 in an
exemplar cell paired with those shown for SERCA2a and
SERCA2b, with the dimensions of the cell provided by a typical
bright field image (panel a), with adjacent images of a three-
dimensional reconstruction of a Z-stack of images with the dis-
tribution of RyR1 labeling in red relative to the DAPI-labeled
nucleus in blue (panel b), and the three-dimensional recon-
struction again (panel c), but this time with the distribution of
labeling depicted by color across the three different volumes
within the cell, namely the perinuclear region (orange; within
1.5 mof, but excluding, the DAPI-labeled nucleus), the extra-
perinuclear region (pink), and the subplasmalemmal region
(light blue; within 1.5mof the plasmamembrane). Analysis of
the distribution by density of RyR1 labeling identified a pro-
gressive, although nonsignificant, increase in the density of
RyR1 labeling from0.0211 0.005m3/m3 in the perinuclear
region, to 0.036  0.007 m3/m3 in the extraperinuclear
region and then to 0.046 0.008m3/m3 in the subplasmale-
mmal region where the majority of SERCA2b labeling was tar-
geted (Fig. 3D, n  15). In cells labeled for RyR2 (Fig. 3B), the
distribution of labeling by density was different. Labeling by
density was lowest in the perinuclear region at 0.022  0.01
m3/m3, markedly higher in the extraperinuclear region
measuring 0.072 0.01m3/m3 and then declined to 0.045
0.01m3/m3 in the subplasmalemmal region. In fact, labeling
for RyR2 in the extraperinuclear region was not only markedly
higher than that observed in the other two regions but was also
2–3-fold greater by density than labeling for either RyR1 or
RyR3 within this region (Fig. 3D, n 10; p 0.05). In marked
contrast to either RyR1 or RyR2 but consistent with the distri-
bution of SERCA2a, Fig. 3C shows that labeling for RyR3 was
almost entirely restricted to the perinuclear region of pulmo-
nary arterial smoothmuscle cells. Labeling by densitymeasured
0.1  0.01 m3/m3 in the perinuclear region compared with
0.02 0.01m3/m3 (p 0.05) in the extraperinuclear region
and 0.003  0.001 m3/m3 (p  0.01) in the subplasmale-
mmal region (Fig. 3D, n 10).
These findings suggest that SERCA2a and RyR3 comprise a
functionally segregated region of the SR proximal to the
nucleuswithin pulmonary arterial smoothmuscle cells. By con-
trast, it would appear that SERCA2b together with RyR1 may
comprise a second, segregated SR compartment proximal to
the plasma membrane. Between each of these, there appears to
be a further region of the SR in which RyR2 is the predominant
RyR subtype but with no clearly designated SERCA. Therefore,
the SR within this region may receive Ca2 from SERCA2a
and/or SERCA2b because of the continuous nature of the SR
Ca2 store (12).
A Cyclopiazonic Acid-insensitive SR Ca2 Store Underpins
Calcium Signaling in Response to Endothelin-1—Previously we
have shown that cyclopiazonic acid, a SERCAantagonist, inhib-
its vasodilation mediated by adenylyl cyclase-coupled -adre-
noreceptors (9), that is mediated, in part, by cAMP-dependent
protein kinase- and cyclic ADP-ribose-dependent SR Ca2
release via RyRs and consequent hyperpolarization that is
driven by the subsequent recruitment of BKCa channels. We
have also reported that a different SERCA antagonist, thapsi-
gargin, blocks global Ca2waves triggered by the vasoconstric-
tor endothelin-1 (ET-1) (36). Importantly, in pulmonary arte-
rial smooth muscle cells the ET-1-induced Ca2 transient is
mediated by an increase in nicotinic acid adenine dinucleotide
phosphate levels, which triggers Ca2 bursts from lysosomes
that are subsequently amplified by Ca2-induced Ca2 release
from the SR via RyRs but not via IP3 receptors (36, 37), and this
has since been confirmed to be the case in coronary arterial
smooth muscle cells (38). Given that previous studies on arte-
rial smooth muscle cells had demonstrated the capacity of
cyclopiazonic acid to deplete one of two releasable pools of
Ca2 within the SR (5), we therefore sought to determine
whether or not cyclopiazonic acid and thapsigargin were
equally effective at blocking global Ca2 waves triggered by
ET-1. Consistent with the proposal that different SERCA may
serve functionally discrete SR compartments in pulmonary
arterial smooth muscle, we observed quite different effects of
these two different SERCA inhibitors. Fig. 4A shows a Ca2
transient induced by ET-1 (100 nM) in an isolated pulmonary
arterial smooth muscle cell, as indicated by an increase in the
Fura-2 fluorescence ratio (F340/F380) from 0.49 0.02 to 1.83
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0.03 (n  31). This remained unaffected following (Fig. 4B)
preincubation (20 min) with cyclopiazonic acid (10 M), with
the Fura-2 fluorescence ratio rising from 0.59 0.03 to 1.79
0.05 (n 31). In marked contrast, Fig. 4C shows that the Ca2
transient induced by ET-1 was virtually abolished following
preincubation (20 min) with thapsigargin (1 M), the Fura-2
fluorescence ratio increasing from 0.52  0.02 to 0.56  0.03
(n  15, p  0.01). This fact is emphasized by the bar chart
shown in Fig. 4D, which compares the means  S.E. for the
percentage increase in the Fura-2 fluorescence ratio at the peak
of the Ca2 transient induced by ET-1 under each condition.
Thus, ET-1 triggers Ca2 release from a cyclopiazonic acid-
insensitive store in pulmonary arterial smoothmuscle, whereas
vasodilation by -adrenoreceptor activation is mediated by
Ca2 release from a cyclopiazonic acid-sensitive SR store (9). In
each case Ca2 release has been shown to occur via RyRs, but
with respect to vasodilation by -adrenoreceptor activation, it
is clear that the RyRs activated must sit proximal to the plasma
membrane, because the released Ca2 promotes vasodilation
by opening BKCa channels (9). Therefore, these findings are
entirely consistent with the presence of two functionally segre-
gated SR Ca2 stores being fed by two different SERCA sub-
types, from which Ca2 may be released via different popula-
tions of RyRs to elicit vasoconstriction and/or vasodilation.
Given that SERCA2b and RyR1, but not SERCA2a or RyR3, sit
proximal to the plasma membrane, it seems likely that
SERCA2b supplies Ca2 to a peripheral SR store that may be
released via RyR1 to promote vasodilation in response to -ad-
renoreceptor activation. By contrast SERCA2a and RyR3, likely
coupled by Ca2-induced Ca2 release to RyR2 in the perinu-
clear/extraperinuclear region (18), comprise the SR compart-
ment responsible for initiation of propagating global Ca2
waves and vasoconstriction. Moreover, these data suggest that
SERCA2b exhibits a greater sensitivity to block by cyclopia-
zonic acid than does SERCA2a, at least under the conditions of
our experiments.
DISCUSSION
In agreement with previous studies on vascular smoothmus-
cle (32), our findings suggest that SERCA2a and SERCA2b are
functionally expressed in pulmonary arterial smooth muscle.
Strikingly, the vast majority of SERCA2b labeling (72%) lay
within the subplasmalemmal region (within 1.5 m of the
plasmamembrane). Inmarked contrast, SERCA2a labeling was
almost entirely (90%) restricted to the perinuclear region of
pulmonary arterial smooth muscle cells (within 1.5 m of the
perimeter of the nucleus). Consistent with the distribution of
SERCA2a, RyR3 was almost entirely restricted to the perinu-
clear region (70%). By contrast, RyR1 labeling was maximal
in the subplasmalemmal region. These findings suggest that
SERCA2a and RyR3 comprise a functionally segregated region
of the SR proximal to the nucleus, whereas SERCA2b and RyR1
comprise a second, functionally segregated SR compartment
proximal to the plasmamembrane. Between these two regions,
i.e. within the extraperinuclear volume, labeling for RyR2 was
predominant, but with no clearly designated SERCA. The SR
within this region may therefore receive Ca2 from SERCA2a
and/orSERCA2bbecauseof the continuousnatureof theSRCa2
store (12).Thiswouldbe consistentwith the view thatRyR2 serves
to carry, by Ca2-induced Ca2 release, a propagating Ca2wave
away from lysosome-SR junctions that sit within the perinuclear
region, which cannot be achieved by RyR3 because it is restricted
to the perinuclear region of the cell (18).
That theremay be discrete SR compartments is supported by
previous studies on arterial smoothmuscle, the pulmonary vas-
culature included, and airway smooth muscle (4–7, 9, 11). In
this respect, for each type of smooth muscle studied, the one
key piece of evidence was that the SERCA pump antagonist
cyclopiazonic acid exhibits the capacity to selectively deplete
one of at least two functionally segregated SR compartments.
Consistent with this view, we have previously shown that cyclo-
piazonic acid inhibits vasodilation of pulmonary arteries in
response to -adrenoreceptor activation by isoprenaline,
which is mediated, in part, by Ca2 release proximal to the
plasma membrane via RyRs, consequent recruitment of plas-
malemmal BKCa channels, smooth muscle cell hyperpolariza-
tion, and ultimately pulmonary artery dilation (9). In marked
contrast to the block by cyclopiazonic acid of SRCa2 release in
response to -adrenoreceptor activation (9), we showed here
FIGURE 4. A cyclopiazonic acid-insensitive sarcoplasmic reticulum Ca2 store underpins Ca2 signaling in response to ET-1 in pulmonary arterial
smoothmuscle cells.A–C, the effect on the Fura-2 fluorescence ratio (F340/F380) in the absence (A) and presence of cyclopiazonic acid (B) and thapsigargin (C).
D, bar chart shows themeans S.E. for the percentage change in Fura-2 fluorescence ratio induced by ET-1 in the absence and presence of cyclopiazonic acid
(CPA) and thapsigargin (Thapsi), respectively.
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that global Ca2 signals induced by ET-1, which are also carried
by RyRs in pulmonary arterial smooth muscle cells, remained
unaffected following preincubation with cyclopiazonic acid,
but were abolished by preincubation of pulmonary arterial
smoothmuscle cells with thapsigargin, even though both drugs
are SERCA antagonists. Thus, it seems likely that a cyclopia-
zonic acid-sensitive SERCA pump (SERCA2b) serves the SR
compartment proximal to the plasma membrane, from which
Ca2 release via RyRs recruits plasmalemmal BKCa channels to
elicit smooth muscle cell hyperpolarization and pulmonary
artery dilation (9), whereas a SERCA pump that is relatively
insensitive to cyclopiazonic acid (SERCA2a) serves a discrete
SR compartment that underpins pulmonary artery constric-
tion. Therefore, it is surprising to note that cell-free assays on
recombinant SERCA2a and SERCA2b have shown that both
cyclopiazonic acid and thapsigargin are effective inhibitors of
both isoforms (39, 40). Thus, the preferential depletion of the
peripheral SR store by cyclopiazonic acid is most likely due
to its pharmacokinetics providing for “selective access” to
SERCA2b over SERCA2a in a manner that may be determined
by the local cytoplasmic environment (e.g.pHandATP concen-
tration) (41–43), the relative hydrophobicity of cyclopiazonic
acid (Kp 3.1) and thapsigargin (Kp 4.9), and/or the fact that the
affinity of cyclopiazonic acid for SERCA is 1,000 times lower
than that of thapsigargin (44). However, in recombinant sys-
tems, it has been shown that SERCA2b can be selectively inhib-
ited by monovalent cations such as Cs (45). Furthermore,
cyclopiazonic acid and thapsigargin occupy different nonover-
lapping binding sites in the ATPase (43), and site-directed
mutagenesis of SERCA can selectively reduce the affinity of
cyclopiazonic acid relative to thapsigargin (46). Thus, we can-
not rule out the possibility that post-translational modifica-
tions could confer a pharmacology distinct from that exhibited
by recombinant SERCA.
Given our findings, it may be important to note that
SERCA2a and SERCA2b exhibit distinct kinetics. SERCA2b,
which our data suggest serves a peripheral SR store that under-
pins Ca2-dependent vasodilation, has a higher affinity for
Ca2 but a lower Vmax than SERCA2a (47–49), which our data
suggest serves a central SR compartment that supports vaso-
constriction. SERCA2b may therefore be dominant at rest and
function to maintain resting levels of Ca2 in the vicinity of the
contractile apparatus. However, its low Vmax may lead to satu-
ration of this SERCA with Ca2 upon release of Ca2 from the
central SR compartment in response to stimuli that elicit vaso-
constriction. Thereby, SERCA2b would allow the Ca2 con-
centration to rise in the vicinity of the contractile apparatus,
until such time as vasodilation is promoted by adenylyl cyclase-
coupled receptors thatmay: 1) increase the activity of SERCA2b
by phosphorylation via cAMP-dependent protein kinase (50,
51) and facilitate the removal of Ca2 from the greater cyto-
plasm and 2) trigger Ca2 release from the peripheral SR store
via RyRs in a manner mediated by cAMP-dependent protein
kinase, leading to plasma membrane hyperpolarization and
secondary facilitation of Ca2 sequestration from the junc-
tional space between the SR and the plasma membrane via the
Na/Ca2 exchanger (2, 52) and/or plasma membrane Ca2-
ATPase (Fig. 5). This has a physiological precedent in that it
mirrors somewhat the roles of uptake 1 and uptake 2 at nora-
drenergic synapses, which are also dependent on the relative
affinity and Vmax of these two catecholamine transporters.
In summary, the present investigation provides evidence in
support of the view that there may be two functionally segre-
gated SRCa2 stores within pulmonary arterial smoothmuscle
cells, each served by a different SERCA pump. One may lie in
close apposition to the plasma membrane, is likely served by
SERCA2b, and likely releases Ca2 via RyR1 to promote pul-
monary artery dilation (9). The other appears to be located cen-
trally, is served by SERCA2a, and releases Ca2 via RyR3, which
may in turn recruit RyR2 byCa2-inducedCa2 release to elicit
a propagating global Ca2 wave (18) and consequent pulmo-
nary artery constriction (10, 11, 18).
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